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Danny R. Youlden1, Philippa H. Youl1,2,3, H Peter Soyer4, Lin Fritschi5 and Peter D. Baade1,2,3
The relatively high incidence of Merkel cell carcinoma (MCC) in Queensland provides a valuable opportunity to
examine links with other cancers. A retrospective cohort study was performed using data from the Queensland
Cancer Registry. Standardized incidence ratios (SIRs) were used to approximate the relative risk of being
diagnosed with another primary cancer either following or prior to MCC. Patients with an eligible first primary
MCC (n¼ 787) had more than double the expected number of subsequent primary cancers (SIR¼ 2.19, 95%
confidence interval (CI)¼ 1.84–2.60; Po0.001). Conversely, people who were initially diagnosed with cancers other
than MCC were about two and a half times more likely to have a subsequent primary MCC (n¼ 244) compared
with the general population (SIR¼ 2.69, 95% CI¼ 2.36–3.05; Po0.001). Significantly increased bi-directional relative
risks were found for melanoma, lip cancer, head and neck cancer, lung cancer, myelodysplastic diseases, and
cancer with unknown primary site. In addition, risks were elevated for female breast cancer and kidney cancer
following a first primary MCC, and for subsequent MCCs following first primary colorectal cancer, prostate
cancer, non-Hodgkin lymphoma, or lymphoid leukemia. These results suggest that several shared pathways are
likely for MCC and other cancers, including immunosuppression, UV radiation, and genetics.
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INTRODUCTION
Merkel cell carcinoma (MCC) is an uncommon but aggressive
form of skin cancer (Poulsen, 2004; Taylor et al., 2005;
Donepudi et al., 2012; Prieto Munoz et al., 2013). Prognosis
is often poor because the tumors tend to grow rapidly with a
high risk for early metastasis (Donepudi et al., 2012;
Nicolaidou et al., 2012; Prieto Munoz et al., 2013).
Apart from old age, the main known risk factors for MCC
are exposure to UV radiation and immunosuppression
(Poulsen, 2004; Pulitzer et al., 2009; Agelli et al., 2010;
Becker, 2010; Donepudi et al., 2012; Nicolaidou et al., 2012),
although it is yet to be determined to what degree the latter
two factors work together (Schrama et al., 2012). A predo-
minantly viral etiology appears likely given that a human
pathogen called Merkel cell polyomavirus (MCPyV; Feng
et al., 2008; Spurgeon and Lambert, 2013) has been dis-
covered in up to 90% of cases in North America and Europe
(Donepudi et al., 2012; Prieto Munoz et al., 2013). However,
there has been some speculation that sun exposure may
generate a greater contribution to the incidence of MCC in
parts of Australia because of elevated levels of ambient UV
radiation (Girschik et al., 2011). Our recent finding (Youlden
et al., 2014) that the incidence rate of MCC is twice as high in
Queensland than anywhere else in the world and up to seven
times higher than rates in some countries in northern Europe
may provide support for the hypothesis that a larger proportion
of MCCs in Australia are sun related.
Studies examining the occurrence of multiple cancers in
the same person can contribute toward an understanding of
the etiology of cancer. Although several previous international
studies have reported that people diagnosed with MCC are at
increased risk of other primary cancers (Brenner et al., 2001;
Howard et al., 2006; Gass et al., 2010; Kaae et al., 2010;
Koljonen et al., 2010; Bzhalava et al., 2011; Tadmor et al.,
2012), Australia is well recognized as being a unique
environment in terms of high UV exposure, outdoor lifestyle,
and a predominately Caucasian population. This combination
of factors provides an ideal opportunity to investigate whether
people in Australia who are diagnosed with MCC are more
likely than the general population to develop other sun-related
cancers, thus adding to the body of evidence regarding
whether MCCs are also related to sun exposure. The aim of
the present work was therefore to examine the occurrence of
multiple primary cancers within a large cohort of MCC
patients and determine how the results compare with other
parts of the world.
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RESULTS
Study cohorts
First primary MCC. A total of 815 cases of first primary MCC
were recorded for Queensland residents between 1982 and 2010.
Those who had less than 2 months of follow-up from the time of
diagnosis (n¼ 28) were excluded from the analysis, leaving 787
cases (97%) of first primary MCC remaining in the study. About
two-thirds (65%) of these MCC patients were males and the age
at diagnosis ranged from 29 to 104 with a median of 75 years.
The cohort of patients with a first primary MCC accumulated
3,377 years of follow-up in total (median¼ 2.2 years).
Other first primary cancers. The cohort of all first primary
cancers (excluding MCC) diagnosed between 1982 and 2010
included 357,753 individuals with a total follow-up of 2,308,416
years (median¼ 4.2 years). Males (55%) outnumbered females,
and the median age at diagnosis was 64 years. More than half
(55%) of the other first primary cancers were either melanoma,
prostate cancer (both 14%), breast cancer, or colorectal cancer
(13% each).
Subsequent primary cancers following a first primary MCC
Of the 787 eligible cases of first primary MCC, 119 patients
(15%) were diagnosed with a total of 135 subsequent primary
cancers by the end of 2011. As shown in Table 1, the most
common types of subsequent primary cancers were melanoma
(15%), prostate cancer (11%), lung cancer (10%), and colo-
rectal cancer (9%). About one-quarter (n¼30, 22%) of the
subsequent cancers were diagnosed within the first 12 months
of the initial MCC diagnosis and the remainder (n¼105, 78%)
were diagnosed 1 or more years afterward.
People with MCC had more than double the risk (standar-
dized incidence ratio (SIR)¼ 2.19, 95% confidence interval¼
1.84–2.60; Po0.001) of being diagnosed with a subsequent
primary cancer compared with the general population. Ele-
vated SIRs (Table 1) were found for each of the various types of
skin cancer—i.e., MCC, melanoma, and the grouping of other
cancers of the skin (excluding basal cell carcinomas (BCCs)
and squamous cell carcinomas (SCCs) of the skin). There was
also a significant excess of lip cancer, head and neck cancer,
and cancer with unknown primary site among MCC patients,
even when subsequent cancers were restricted to those
diagnosed at least 1 year after MCC. In contrast, SIRs were
only statistically significant for lung, breast, and kidney cancers
and myelodysplastic diseases when tumors diagnosed within
the first year were included. There was no significant increase
in risk for either non-Hodgkin lymphoma or lymphoid leuke-
mia following a first primary MCC.
Subsequent primary MCCs following a first primary cancer
Between 1982 and 2011, 272 subsequent primary MCCs
were diagnosed. After excluding those cases in which less
than 2 months had elapsed after the diagnosis of the first
primary cancer, cases in which the first primary cancer was
diagnosed before 1982 or after 2010, or when there were
multiple records of MCC for the same person (n¼28), 244
(90%) eligible cases of subsequent primary MCC remained.
Again this group comprised predominantly males (75%) with
a slightly older median age at diagnosis of subsequent
primary MCCs (78 years old) compared with the first primary
MCCs.
The most frequent types of first primary cancer before MCC
were melanoma (25%), prostate cancer (16%), colorectal
cancer (11%), and lip cancer (7%). Most (n¼ 221, 91%) of
the cases of MCC in the study that occurred subsequent
to another first primary cancer were diagnosed more than
1 year after the initial cancer.
Compared with the general population, cancer survivors
were about two and a half times more likely to be diagnosed
with a subsequent primary MCC (SIR¼2.69, 95% confidence
interval¼2.36–3.05; Po0.001). The largest relative risks
occurred for patients with cancer of unknown primary site,
lip cancer, and lymphoid leukemia (all with SIR48; Table 2).
Significant SIRs were also found following myelodysplastic
diseases, melanoma, head and neck cancer, non-Hodgkin
lymphoma, lung cancer, colorectal cancer, and prostate
cancer. Furthermore, all of these risks remained elevated
when only MCCs diagnosed more than 1 year after the first
primary cancer were considered. No significant association
with subsequent primary MCC was observed for first primary
stomach, bladder, kidney, breast, or gynecological cancers.
DISCUSSION
In this study, we have examined the occurrence of multiple
primary cancers associated with MCC in a population that has
the highest incidence rates of MCC in the world (Youlden
et al., 2014). Apart from a few studies based on small-
to-medium-sized cohorts (all with no350) (Brenner et al.,
2001; Gass et al., 2010; Kaae et al., 2010; Koljonen et al.,
2010; Tadmor et al., 2012), only two large population-based
studies from the United States (Howard et al., 2006; n¼ 1306)
and Scandinavia (Bzhalava et al., 2011; n¼756) have
previously quantified the relative risks for people diagnosed
with MCC. Both of these studies were in locations with
differing physical, demographic, and cultural environments
compared with Queensland, combined with a much lower
underlying population incidence of MCC. Thus, the current
study represents a valuable addition to the existing literature.
The overall increased relative risk of a subsequent malig-
nancy among MCC patients in our study was equivalent
to those reported in some of the smaller studies (Brenner
et al., 2001; Kaae et al., 2010; Koljonen et al., 2010), but
considerably higher than that reported in the United States
(Howard et al., 2006; SIR¼ 1.2) or Scandinavia (Bzhalava
et al., 2011; SIR¼1.4). Only two studies (Howard et al., 2006;
Kaae et al., 2010) have reported separate results for the risks of
MCC following other first primary cancers. Again, the relative
risk for subsequent MCCs in Queensland was much greater
than that in the United States (Howard et al., 2006; SIR¼ 1.4)
but similar to Denmark (Kaae et al., 2010; SIR¼2.6). It should
be noted that the results from the United States probably
provide the most valid benchmark for the Queensland data
because the overall SIRs from other countries have included
keratinocyte cancers (basal cell carcinomas and/or SCCs of the
skin), which have been found to have very high SIRs (Kaae
et al., 2010; Koljonen et al., 2010; Bzhalava et al., 2011) and
would most likely elevate the total relative risk.
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Although MCC is known to occur with other cutaneous
tumors and some solid tumors, the strongest associations have
been found for hematological malignancies, particularly
chronic lymphocytic leukemia (Howard et al., 2006; Kaae
et al., 2010; Tadmor et al., 2012). Despite an increased
bi-directional risk between MCC and total lymphohemato-
poietic cancers (which includes all leukemias, lymphomas,
and any other neoplasms of lymphatic or hematopoietic
tissue) in Queensland, we did not observe a significant SIR
for either lymphoid leukemia or non-Hodgkin lymphoma
following MCC, unlike some other studies (Howard et al.,
2006; Kaae et al., 2010). We did, however, find a greater
than expected number of MCCs that were diagnosed after
lymphoid leukemia or non-Hodgkin lymphoma (Howard
et al., 2006; Kaae et al., 2010).
Some of the strongest associations with other cancers
for people in Queensland diagnosed with MCC were for
sun-related tumors. Large, bi-directional relative risks were
found for both melanoma and lip cancer. Significant relation-
ships between melanoma either following (Bzhalava et al.,
2011) or before (Howard et al., 2006; Kaae et al., 2010)
MCC have been reported previously, with SIRs of a similar
magnitude to those reported here.
In agreement with our findings, increased SIRs for female
breast cancer (Koljonen et al., 2010) and certain types of head
and neck cancer (such as cancer of the larynx (Bzhalava et al.,
2011) or salivary glands (Howard et al., 2006)) have been
observed by other researchers following a first primary MCC,
whereas an excess of MCC following cancer of the respiratory
organs was also found in an earlier study (Howard et al., 2006).
In addition, we found significantly increased bi-directional risks
for myelodysplastic diseases and cancer with unknown primary
site, as well as for kidney cancer following MCC (within the
first year of diagnosis only) and for MCC after first primary
colorectal and prostate cancers; none of these associations
with MCC have been documented until now.
Table 1. Standardized incidence ratios for multiple primary cancers1 following Merkel cell carcinoma, Queensland,
1982–2011
Cancers occurring after 2 months Cancers occurring after 1 year
Type of second primary
cancer (ICD-O-3 code)
Observed
number
Expected
number SIR (95% CI)2 P-value
Observed
number
Expected
number SIR (95% CI)2 P-value
Total second primary cancers (C00-C80) 135 61.5 2.19 (1.84–2.60) o0.001 105 56.2 1.87 (1.53–2.26) o0.001
Total skin cancers (C44) 29 5.7 5.05 (3.38–7.26) o0.001 24 5.2 4.58 (2.94–6.82) o0.001
Melanoma (C44, M872-M879) 20 5.3 3.77 (2.30–5.83) o0.001 16 4.8 3.31 (1.89–5.37) 0.001
Merkel cell carcinoma (C44, M8247) ** ** 17.5 (4.78–44.9) o0.001 ** ** 14.4 (2.96–42.0) 0.003
Other skin (excl. BCC/SCC–C44 other) ** ** 24.0 (7.79–56.0) o0.001 ** ** 26.2 (8.52–61.2) o0.001
Total other solid tumors3 85 47.1 1.80 (1.44–2.23) o0.001 63 43.0 1.46 (1.13–1.87) 0.005
Lip (C00) ** ** 6.12 (1.67–15.7) 0.009 ** ** 5.03 (1.04–14.7) 0.046
Head and neck (C01-C14, C30-C32) 7 1.5 4.81 (1.93–9.91) 0.002 7 1.3 5.28 (2.12–10.9) 0.001
Stomach (C16) ** ** 1.84 (0.38–5.37) 0.492 ** ** 2.01 (0.41–5.86) 0.380
Colorectal (C18-C20, C218) 12 9.5 1.27 (0.65–2.21) 0.492 8 8.7 0.92 (0.40–1.82) 0.730
Lung (C33-C34) 13 6.4 2.03 (1.08–3.47) 0.029 10 5.9 1.71 (0.82–3.14) 0.149
Breast—females (C50) 9 3.7 2.44 (1.12–4.64) 0.027 6 3.4 1.76 (0.64–3.82) 0.263
Gynecological (C51-C58) ** ** 2.69 (0.73–6.90) 0.128 ** ** 2.90 (0.79–7.43) 0.103
Prostate (C61) 15 14.4 1.04 (0.58–1.72) 0.935 11 13.0 0.85 (0.42–1.52) 0.709
Kidney (C64-C66, C68) 5 1.5 3.25 (1.06–7.59) 0.041 ** ** 2.85 (0.78–7.30) 0.108
Bladder (C67) ** ** 1.23 (0.25–3.58) 0.885 ** ** 0.45 (0.01–2.49) 0.692
Other solid tumors 10 5.9 1.71 (0.82–3.14) 0.148 6 5.4 1.12 (0.41–2.44) 0.891
Total lymphohematopoietic cancers (M959-M998) 14 6.1 2.29 (1.25–3.85) 0.008 11 5.6 1.97 (0.98–3.53) 0.055
Non-Hodgkin lymphoma (M965-M966) 5 2.0 2.50 (0.81–5.83) 0.105 ** ** 2.19 (0.60–5.61) 0.226
Lymphoid leukemia (M982-M983) ** ** 0.00 (0.00–3.50) 0.849 ** ** 0.00 (0.00–3.83) 0.915
Myelodysplastic cancers (M998) ** ** 5.33 (1.45–13.6) 0.015 ** ** 4.36 (0.90–12.7) 0.066
Other lymphohematopoietic cancers 5 2.5 2.00 (0.65–4.68) 0.216 ** ** 1.75 (0.48–4.49) 0.394
Unknown primary site (C80) 7 2.6 2.68 (1.08–5.53) 0.035 7 2.4 2.93 (1.18–6.03) 0.023
Abbreviations: CI, confidence interval; excl., excluding; SIR, standardized incidence ratio; **, observed number o5.
1Excludes subsequent primary cancers occurring within 2 months of the first primary MCC.
2Statistically significant SIRs (Po0.05) are shown in bold.
3Total other solid tumors excludes skin cancers (C44), lymphohematopoietic diseases (M959-M998), and cancers with unknown primary site (C80).
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Despite breakthroughs in the understanding of MCC in
recent years, much remains unknown about how it originates
(Agelli et al., 2010; Nicolaidou et al., 2012; Prieto Munoz
et al., 2013). Immunosuppression was identified as a risk
factor for MCC following case reports for organ transplant
recipients (Kempf et al., 2013) and HIV/AIDS patients (Engels
et al., 2002). The subsequent discovery of MCPyV has led to a
greater understanding of the pathogenesis of MCC, but the
exact processes involved are yet to be determined, such as
how the virus invades Merkel cells (Bhatia et al., 2011; Chang
and Moore, 2012).
Investigations such as the current one are important because
excesses of particular types of cancer either before and/or after
a diagnosis of MCC may suggest a common etiology,
particularly when bi-directional associations are present.
One such possibility is the potential involvement of MCPyV
in other cancers (Kaae et al., 2010; Bzhalava et al., 2011).
MCPyV is thought to have a suspected role in the pathogenesis
of certain types of leukemia and lymphoma (Pantulu et al.,
2010; Teman et al., 2011). For example, mutations of the large
T antigen of MCPyV have been found in the presence of both
MCC and chronic lymphoid leukemia and are thought to
explain at least some of their co-occurrence (Pantulu et al.,
2010). A viral mechanism may also provide a plausible
explanation for the association of MCC with head and neck
cancers (D’Souza and Dempsey, 2011). Our data provide
support for these theoretical associations. Moreover, it has
been reported that the treatment with immune-suppressive
agents such as purine analogs for some previous lympho-
proliferative malignancies may exacerbate existing immuno-
suppression, thus putting patients at possible increased risk of
developing MCC (Tadmor et al., 2012).
In addition, MCC may share nonviral risk factors with other
tumors (Kaae et al., 2010). Of particular interest in the current
study is the potential involvement of UV radiation. Given the
established role of excess sun exposure in the development of
melanoma (IARC Working Group on the Evaluation of
Carcinogenic Risks to Humans, 2009), it is highly plausible
(Miller and Rabkin, 1999; Agelli et al., 2010; Bzhalava et al.,
2011) that this contributes to the large relative risks of being
Table 2. Standardized incidence ratios for Merkel cell carcinoma1 following other first primary cancers, Queensland,
1982–2011
MCCs occurring after 2 months MCCs occurring after 1 year
Type of first primary cancer
(ICD-O-3 code)
Observed
number
Expected
number SIR (95% CI)2 P-value
Observed
number
Expected
number SIR (95% CI)2 P-value
Total first primary cancers (C00-C80) 244 90.8 2.69 (2.36–3.05) o0.001 221 85.8 2.57 (2.25–2.94) o0.001
Total skin cancers (C44) 65 13.7 4.73 (3.65–6.03) o0.001 61 13.3 4.58 (3.50–5.88) o0.001
Melanoma (C44, M872-M879) 63 13.4 4.69 (3.60–6.00) o0.001 59 13.0 4.53 (3.45–5.84) o0.001
Total other solid tumors3 139 69.1 2.01 (1.69–2.37) o0.001 126 65.2 1.93 (1.61–2.30) o0.001
Lip (C00) 17 1.9 8.81 (5.13–14.1) o0.001 15 1.9 8.04 (4.50–13.3) o0.001
Head and neck (C01-C14, C30-C32) 11 2.4 4.51 (2.25–8.08) o0.001 11 2.3 4.77 (2.38–8.54) o0.001
Stomach (C16) ** ** 2.74 (0.57–8.01) 0.197 ** ** 2.05 (0.25–7.41) 0.510
Colorectal (C18-C20, C218) 28 15.5 1.80 (1.20–2.61) 0.006 27 14.7 1.83 (1.21–2.67) 0.005
Lung (C33-C34) 7 2.5 2.84 (1.14–5.85) 0.026 6 2.0 2.94 (1.08–6.41) 0.036
Breast—females (C50) 10 8.6 1.16 (0.56–2.13) 0.725 8 8.3 0.96 (0.42–1.90) 0.822
Gynecological (C51-C58) ** ** 1.09 (0.23–3.19) 0.963 ** ** 0.76 (0.09–2.74) 0.520
Prostate (C61) 40 26.3 1.52 (1.09–2.07) 0.015 38 24.8 1.53 (1.08–2.10) 0.016
Kidney (C64-C66, C68) ** ** 1.41 (0.29–4.13) 0.713 ** ** 0.99 (0.12–3.57) 0.800
Bladder (C67) 6 4.2 1.44 (0.53–3.12) 0.487 6 4.0 1.49 (0.55–3.25) 0.434
Other solid tumors 11 3.9 2.86 (1.43–5.11) 0.004 9 3.5 2.58 (1.18–4.90) 0.019
Total lymphohematopoietic cancers (M959-M998) 30 7.0 4.31 (2.91–6.15) o0.001 24 6.5 3.72 (2.38–5.53) o0.001
Non-Hodgkin lymphoma (M965-M966) 10 2.6 3.80 (1.82–6.99) 0.001 8 2.5 3.25 (1.40–6.41) 0.008
Lymphoid leukemia (M982-M983) 12 1.4 8.45 (4.37–14.8) o0.001 12 1.3 8.90 (4.60–15.6) o0.001
Myelodysplastic cancers (M998) ** ** 6.78 (1.85–17.4) 0.006 ** ** 5.74 (1.18–16.8) 0.032
Other lymphohematopoietic cancers ** ** 1.73 (0.47–4.42) 0.409 ** ** 0.47 (0.01–2.63) 0.748
Unknown primary site (C80) 10 0.9 10.7 (5.11–19.6) o0.001 10 0.8 12.0 (5.77–22.1) o0.001
Abbreviations: CI, confidence interval; SIR, standardized incidence ratio; **, observed number o5.
1Excludes subsequent primary MCCs occurring within 2 months of the first primary cancer.
2Statistically significant SIRs (Po0.05) are shown in bold.
3Total other solid tumors excludes skin cancers (C44), lymphohematopoietic diseases (M959-M998), and cancers with unknown primary site (C80).
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diagnosed with melanoma either before or after MCC
that were observed. Furthermore, a positive association has
been identified between UV radiation and lip cancer (IARC
Working Group on the Evaluation of Carcinogenic Risks to
Humans, 2009); hence, our finding of the co-occurrence of
MCC with lip cancer in Queensland may point to sun
exposure as a shared cause.
Another possibility is that sunlight and MCPyV may act in
combination. In particular, researchers have demonstrated that
UV radiation can regulate the level of MCPyV replication, thus
providing a potential explanation for the association between
MCC and sun exposure (Mogha et al., 2010).
Genetic links between MCC and other cancers have also
been proposed, particularly those of neuroendocrine origin
(including melanoma; Vortmeyer et al., 1998). It is feasible
that some of the unexplained associations that we have
reported here may have a very specific underlying genetic
pathway, similar to the relationship for melanoma and kidney
cancer in persons with a MITF-E318K mutation as described
by Bertolotto et al. (2011).
A significant excess of head and neck cancers, female breast
cancer, and kidney cancer has been previously reported
among melanoma survivors in Queensland (Youlden and
Baade, 2011). However, it is not clear what, if any,
etiological links there may be between MCC, melanoma,
and these other types of cancer.
Caution should be exercised when interpreting and compar-
ing relative risks as opposed to absolute risks. A main strength
of our work is that it involves one of the largest, population-
based groups of MCC cases available. Even with this large
cohort, actual numbers of subsequent cancers are low for
some cancer types, limiting our ability to examine the
associations in more detail. People diagnosed with cancer
are likely to have ongoing contact with medical professionals
and heightened awareness of their health, but it is not possible
to quantify the extent to which this may have influenced our
results. The fact that most of the increased relative risks remain
more than 1 year after the initial diagnosis reduces the
likelihood that subsequent cancers were detected primarily
as a result of increased medical surveillance.
Despite improvements in clinical and histopathological
diagnostic techniques, it remains difficult to distinguish MCC
from other similar skin neoplasms (Jalilian et al., 2013). It is
therefore possible that some cases of MCC have been
incorrectly identified and, conversely, that others have been
excluded, although previous studies of MCC in Australia
suggest that the rate of misclassification is within acceptable
bounds (o5%; Girschik et al., 2011; Youlden et al., 2014).
Another potential limitation is that bi-directional links may
not always be obvious; it is possible that cancers that exhibit
an excess of subsequent MCC but which do not themselves
occur more than expected following a first primary MCC
may be due to the low survival rates for MCC patients, thus
not allowing sufficient time for the other cancer to develop
(Howard et al., 2006). Unlike some other studies, we did
not have information on keratinocyte cancers (basal cell
carcinoma and SCC), the two most common types of non-
melanoma skin cancers.
In summary, the results presented here indicate that MCC
co-occurs with a range of other cancers for people in
Queensland at a rate that is higher than expected. The strong
associations with melanoma and lip cancer are most likely
caused by sun exposure, whereas the lack of an excess for
lymphoid leukemia or non-Hodgkin lymphoma following
MCC (in contrast to other studies) may suggest less of a viral
pathway for MCC in Queensland. In addition, our findings
highlight the requirement for careful and ongoing follow-up
for MCC patients, particularly given that some subsequent
cancers are amenable to early detection, thus increasing the
prospect of successful treatment.
MATERIALS AND METHODS
Data
A population-based de-identified extract containing details for all
cases of invasive cancer diagnosed for residents of Queensland
between 1982 and 2011 was obtained from the Queensland Cancer
Registry. Notification of cancers from hospitals, nursing homes,
and pathology services throughout the state is required by law
(Queensland Cancer Registry et al., 2013). These notifications are
received for every cancer diagnosed (whether primary or recurrent
except for keratinocyte skin cancers) from all Queensland institutions
and for Queensland residents who have moved interstate following
their first cancer diagnosis. Receiving multiple notifications from
these different sources permits the Queensland Cancer Registry to
verify each cancer case reported. A comprehensive validation process
is performed annually, with legislation allowing the Registry to query
notifying institutions if information is missing or the diagnosis is
questionable. Cases that are not stipulated as recurrent are classified
as new primary cancers.
The extract excluded basal cell carcinomas and SCCs of the skin,
which are not routinely collected by most cancer registries in
Australia (Queensland Cancer Registry et al., 2013). SCCs of the lip
and internal body sites are reported.
MCCs were defined as ICD-O-3 code C44 and morphology code
M8247/3. Two groups were studied–patients for whom MCC
occurred as a first primary cancer and those in whom MCC was
diagnosed subsequent to another type of primary cancer. Unique
dummy numbers facilitated the linkage of records when a person had
more than one primary cancer of any site. Other variables in the
extract included sex, age at diagnosis, year and month of diagnosis,
and year and month of death (where applicable).
First primary cancers were restricted to those diagnosed between
1982 and 2010 with data on subsequent primary cancers and/or
mortality available until 31 December 2011. This potentially allowed
at least 1 year of follow-up and a maximum of 30 years.
Any synchronous primary cancers (defined as being diagnosed
within 2 months of the first primary cancer (Howe, 2003)) were
omitted in an effort to minimize detection bias (Curtis et al., 2006).
Multiple subsequent cancers of the same type were also excluded;
i.e., if a person had an MCC followed by two subsequent melanomas,
the second melanoma was omitted.
Statistical analyses
The relative risk of being diagnosed with a subsequent primary cancer
following a first primary MCC was approximated by calculating SIRs.
This method compares the occurrence of subsequent cancers in the
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cohort of interest against what would be expected if the cohort
experienced the same incidence rates as the general population.
The time at risk for each member of the study cohort was measured
from 2 months after diagnosis of the first primary MCC until 31
December 2011, date of death, or date of diagnosis of a subsequent
cancer, whichever came first. Patients who died within 2 months of
their initial diagnosis were effectively excluded as they did not
contribute to the time at risk. The expected number of subsequent
primary cancers was calculated from the product of the person-years
at risk and the incidence rate experienced by the total Queensland
population for a particular type of cancer, stratified by sex, age group,
and year of diagnosis. Estimated SIRs were then obtained by dividing
the observed number of cases by the expected number. Correspond-
ing 95% confidence intervals and P-values were derived on the basis
of a w2-squared distribution (Breslow and Day, 1987).
This procedure was repeated after removing subsequent cancers
diagnosed within the first year following the first primary MCC to
determine whether any increased risks persisted for an extended
period of time. Using the same methods, SIRs were also calculated for
the risk of being diagnosed with a subsequent MCC after a diagnosis
of any other cancer in order to investigate bi-directional risks.
All analyses were conducted using SAS v9.4 for Windows (SAS
Institute, Cary, NC). Ethics approval was not required for this study
because only de-identified data were used.
NOVELTY AND IMPACT
This study examines the occurrence of multiple primary
cancers for people with Merkel cell carcinoma (MCC) in
a population that has the highest incidence rates of MCC in
the world. We were able to identify several significant
associations between MCC and cancers of other sites (such
as the lip, kidney, colon/rectum, and prostate) that have
not been previously described. Our results have the potential
to influence the development of clinical practice guidelines
for MCC.
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